Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 1/2 3Phase EARLY_PHASE1 1

Status

Withdrawn 2Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 13OTHER 6NIH 5

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 2Plasma cell 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 2Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × OTHER × ALT-803 × Clear all
NCT02782546 2026-06-01

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Washington University School of Medicine

Phase 2 Active not recruiting
60 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07355205 2026-05-22

FLINN

Washington University School of Medicine

Phase 2 Not yet recruiting
26 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02989844 2023-11-03

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
20 enrolled 17 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03050216 2023-07-18

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
8 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05007769 2021-11-05

RAN

Washington University School of Medicine

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03003728 2020-07-10

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

University of Arkansas

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡